 | • レポートコード：MRC2-11QY03768 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、152ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は心血管治療薬のグローバル市場について調査・分析したレポートです。種類別（狭心症治療薬、抗不整脈薬、変力薬、その他心血管薬、末梢血管拡張薬、レニン阻害薬、硬化薬、血管拡張薬）市場規模、用途別（小売薬局、病院薬局、オンライン薬局）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別心血管治療薬の競争状況、市場シェア ・世界の心血管治療薬市場：種類別市場規模 2015年-2020年（狭心症治療薬、抗不整脈薬、変力薬、その他心血管薬、末梢血管拡張薬、レニン阻害薬、硬化薬、血管拡張薬） ・世界の心血管治療薬市場：種類別市場規模予測 2021年-2026年（狭心症治療薬、抗不整脈薬、変力薬、その他心血管薬、末梢血管拡張薬、レニン阻害薬、硬化薬、血管拡張薬） ・世界の心血管治療薬市場：用途別市場規模 2015年-2020年（小売薬局、病院薬局、オンライン薬局） ・世界の心血管治療薬市場：用途別市場規模予測 2021年-2026年（小売薬局、病院薬局、オンライン薬局） ・北米の心血管治療薬市場分析：米国、カナダ ・ヨーロッパの心血管治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの心血管治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の心血管治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの心血管治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：AstraZeneca plc.、Pfizer Inc.、Novartis AG、Merck & Co., Inc.、Bristol-Myers Squibb Company、Bayer AG、Sanofi、Boehringer Ingelheim GmbH、F. Hoffmann-La Roche Ltd、Abbott Laboratories、Gilead Sciences, Inc.、Johnson & Johnson、Astellas Pharma, Inc.、Eli Lilly and Company、Otsuka Holdings Co., Ltd.、Takeda Pharmaceutical Company Limited. ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Cardiovascular Agents Market
The global Cardiovascular Agents market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Cardiovascular Agents Scope and Market Size
Cardiovascular Agents market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Cardiovascular Agents market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Cardiovascular Agents market is segmented into
Antianginal Agents
Antiarrhythmic Agents
Inotropic Agents
Miscellaneous Cardiovascular Agents
Peripheral Vasodilators
Renin Inhibitors
Sclerosing Agents
Vasodilators
Segment by Application, the Cardiovascular Agents market is segmented into
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Regional and Country-level Analysis
The Cardiovascular Agents market is analysed and market size information is provided by regions (countries).
The key regions covered in the Cardiovascular Agents market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Cardiovascular Agents Market Share Analysis
Cardiovascular Agents market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Cardiovascular Agents business, the date to enter into the Cardiovascular Agents market, Cardiovascular Agents product introduction, recent developments, etc.
The major vendors covered:
AstraZeneca plc.
Pfizer Inc.
Novartis AG
Merck & Co., Inc.
Bristol-Myers Squibb Company
Bayer AG
Sanofi
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd
Abbott Laboratories
Gilead Sciences, Inc.
Johnson & Johnson
Astellas Pharma, Inc.
Eli Lilly and Company
Otsuka Holdings Co., Ltd.
Takeda Pharmaceutical Company Limited.
1 Study Coverage
1.1 Cardiovascular Agents Product Introduction
1.2 Market Segments
1.3 Key Cardiovascular Agents Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Cardiovascular Agents Market Size Growth Rate by Type
1.4.2 Antianginal Agents
1.4.3 Antiarrhythmic Agents
1.4.4 Inotropic Agents
1.4.5 Miscellaneous Cardiovascular Agents
1.4.6 Peripheral Vasodilators
1.4.7 Renin Inhibitors
1.4.8 Sclerosing Agents
1.4.9 Vasodilators
1.5 Market by Application
1.5.1 Global Cardiovascular Agents Market Size Growth Rate by Application
1.5.2 Retail Pharmacies
1.5.3 Hospital Pharmacies
1.5.4 Online Pharmacies
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Cardiovascular Agents Market Size, Estimates and Forecasts
2.1.1 Global Cardiovascular Agents Revenue 2015-2026
2.1.2 Global Cardiovascular Agents Sales 2015-2026
2.2 Global Cardiovascular Agents, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Cardiovascular Agents Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Cardiovascular Agents Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Cardiovascular Agents Competitor Landscape by Players
3.1 Cardiovascular Agents Sales by Manufacturers
3.1.1 Cardiovascular Agents Sales by Manufacturers (2015-2020)
3.1.2 Cardiovascular Agents Sales Market Share by Manufacturers (2015-2020)
3.2 Cardiovascular Agents Revenue by Manufacturers
3.2.1 Cardiovascular Agents Revenue by Manufacturers (2015-2020)
3.2.2 Cardiovascular Agents Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Cardiovascular Agents Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Cardiovascular Agents Revenue in 2019
3.2.5 Global Cardiovascular Agents Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Cardiovascular Agents Price by Manufacturers
3.4 Cardiovascular Agents Manufacturing Base Distribution, Product Types
3.4.1 Cardiovascular Agents Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Cardiovascular Agents Product Type
3.4.3 Date of International Manufacturers Enter into Cardiovascular Agents Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Cardiovascular Agents Market Size by Type (2015-2020)
4.1.1 Global Cardiovascular Agents Sales by Type (2015-2020)
4.1.2 Global Cardiovascular Agents Revenue by Type (2015-2020)
4.1.3 Cardiovascular Agents Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Cardiovascular Agents Market Size Forecast by Type (2021-2026)
4.2.1 Global Cardiovascular Agents Sales Forecast by Type (2021-2026)
4.2.2 Global Cardiovascular Agents Revenue Forecast by Type (2021-2026)
4.2.3 Cardiovascular Agents Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Cardiovascular Agents Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Cardiovascular Agents Market Size by Application (2015-2020)
5.1.1 Global Cardiovascular Agents Sales by Application (2015-2020)
5.1.2 Global Cardiovascular Agents Revenue by Application (2015-2020)
5.1.3 Cardiovascular Agents Price by Application (2015-2020)
5.2 Cardiovascular Agents Market Size Forecast by Application (2021-2026)
5.2.1 Global Cardiovascular Agents Sales Forecast by Application (2021-2026)
5.2.2 Global Cardiovascular Agents Revenue Forecast by Application (2021-2026)
5.2.3 Global Cardiovascular Agents Price Forecast by Application (2021-2026)
6 North America
6.1 North America Cardiovascular Agents by Country
6.1.1 North America Cardiovascular Agents Sales by Country
6.1.2 North America Cardiovascular Agents Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Cardiovascular Agents Market Facts & Figures by Type
6.3 North America Cardiovascular Agents Market Facts & Figures by Application
7 Europe
7.1 Europe Cardiovascular Agents by Country
7.1.1 Europe Cardiovascular Agents Sales by Country
7.1.2 Europe Cardiovascular Agents Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Cardiovascular Agents Market Facts & Figures by Type
7.3 Europe Cardiovascular Agents Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Cardiovascular Agents by Region
8.1.1 Asia Pacific Cardiovascular Agents Sales by Region
8.1.2 Asia Pacific Cardiovascular Agents Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Cardiovascular Agents Market Facts & Figures by Type
8.3 Asia Pacific Cardiovascular Agents Market Facts & Figures by Application
9 Latin America
9.1 Latin America Cardiovascular Agents by Country
9.1.1 Latin America Cardiovascular Agents Sales by Country
9.1.2 Latin America Cardiovascular Agents Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Cardiovascular Agents Market Facts & Figures by Type
9.3 Central & South America Cardiovascular Agents Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Cardiovascular Agents by Country
10.1.1 Middle East and Africa Cardiovascular Agents Sales by Country
10.1.2 Middle East and Africa Cardiovascular Agents Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Cardiovascular Agents Market Facts & Figures by Type
10.3 Middle East and Africa Cardiovascular Agents Market Facts & Figures by Application
11 Company Profiles
11.1 AstraZeneca plc.
11.1.1 AstraZeneca plc. Corporation Information
11.1.2 AstraZeneca plc. Description and Business Overview
11.1.3 AstraZeneca plc. Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AstraZeneca plc. Cardiovascular Agents Products Offered
11.1.5 AstraZeneca plc. Related Developments
11.2 Pfizer Inc.
11.2.1 Pfizer Inc. Corporation Information
11.2.2 Pfizer Inc. Description and Business Overview
11.2.3 Pfizer Inc. Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Pfizer Inc. Cardiovascular Agents Products Offered
11.2.5 Pfizer Inc. Related Developments
11.3 Novartis AG
11.3.1 Novartis AG Corporation Information
11.3.2 Novartis AG Description and Business Overview
11.3.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Novartis AG Cardiovascular Agents Products Offered
11.3.5 Novartis AG Related Developments
11.4 Merck & Co., Inc.
11.4.1 Merck & Co., Inc. Corporation Information
11.4.2 Merck & Co., Inc. Description and Business Overview
11.4.3 Merck & Co., Inc. Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Merck & Co., Inc. Cardiovascular Agents Products Offered
11.4.5 Merck & Co., Inc. Related Developments
11.5 Bristol-Myers Squibb Company
11.5.1 Bristol-Myers Squibb Company Corporation Information
11.5.2 Bristol-Myers Squibb Company Description and Business Overview
11.5.3 Bristol-Myers Squibb Company Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Bristol-Myers Squibb Company Cardiovascular Agents Products Offered
11.5.5 Bristol-Myers Squibb Company Related Developments
11.6 Bayer AG
11.6.1 Bayer AG Corporation Information
11.6.2 Bayer AG Description and Business Overview
11.6.3 Bayer AG Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Bayer AG Cardiovascular Agents Products Offered
11.6.5 Bayer AG Related Developments
11.7 Sanofi
11.7.1 Sanofi Corporation Information
11.7.2 Sanofi Description and Business Overview
11.7.3 Sanofi Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Sanofi Cardiovascular Agents Products Offered
11.7.5 Sanofi Related Developments
11.8 Boehringer Ingelheim GmbH
11.8.1 Boehringer Ingelheim GmbH Corporation Information
11.8.2 Boehringer Ingelheim GmbH Description and Business Overview
11.8.3 Boehringer Ingelheim GmbH Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Boehringer Ingelheim GmbH Cardiovascular Agents Products Offered
11.8.5 Boehringer Ingelheim GmbH Related Developments
11.9 F. Hoffmann-La Roche Ltd
11.9.1 F. Hoffmann-La Roche Ltd Corporation Information
11.9.2 F. Hoffmann-La Roche Ltd Description and Business Overview
11.9.3 F. Hoffmann-La Roche Ltd Sales, Revenue and Gross Margin (2015-2020)
11.9.4 F. Hoffmann-La Roche Ltd Cardiovascular Agents Products Offered
11.9.5 F. Hoffmann-La Roche Ltd Related Developments
11.10 Abbott Laboratories
11.10.1 Abbott Laboratories Corporation Information
11.10.2 Abbott Laboratories Description and Business Overview
11.10.3 Abbott Laboratories Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Abbott Laboratories Cardiovascular Agents Products Offered
11.10.5 Abbott Laboratories Related Developments
11.1 AstraZeneca plc.
11.1.1 AstraZeneca plc. Corporation Information
11.1.2 AstraZeneca plc. Description and Business Overview
11.1.3 AstraZeneca plc. Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AstraZeneca plc. Cardiovascular Agents Products Offered
11.1.5 AstraZeneca plc. Related Developments
11.12 Johnson & Johnson
11.12.1 Johnson & Johnson Corporation Information
11.12.2 Johnson & Johnson Description and Business Overview
11.12.3 Johnson & Johnson Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Johnson & Johnson Products Offered
11.12.5 Johnson & Johnson Related Developments
11.13 Astellas Pharma, Inc.
11.13.1 Astellas Pharma, Inc. Corporation Information
11.13.2 Astellas Pharma, Inc. Description and Business Overview
11.13.3 Astellas Pharma, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Astellas Pharma, Inc. Products Offered
11.13.5 Astellas Pharma, Inc. Related Developments
11.14 Eli Lilly and Company
11.14.1 Eli Lilly and Company Corporation Information
11.14.2 Eli Lilly and Company Description and Business Overview
11.14.3 Eli Lilly and Company Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Eli Lilly and Company Products Offered
11.14.5 Eli Lilly and Company Related Developments
11.15 Otsuka Holdings Co., Ltd.
11.15.1 Otsuka Holdings Co., Ltd. Corporation Information
11.15.2 Otsuka Holdings Co., Ltd. Description and Business Overview
11.15.3 Otsuka Holdings Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)
11.15.4 Otsuka Holdings Co., Ltd. Products Offered
11.15.5 Otsuka Holdings Co., Ltd. Related Developments
11.16 Takeda Pharmaceutical Company Limited.
11.16.1 Takeda Pharmaceutical Company Limited. Corporation Information
11.16.2 Takeda Pharmaceutical Company Limited. Description and Business Overview
11.16.3 Takeda Pharmaceutical Company Limited. Sales, Revenue and Gross Margin (2015-2020)
11.16.4 Takeda Pharmaceutical Company Limited. Products Offered
11.16.5 Takeda Pharmaceutical Company Limited. Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Cardiovascular Agents Market Estimates and Projections by Region
12.1.1 Global Cardiovascular Agents Sales Forecast by Regions 2021-2026
12.1.2 Global Cardiovascular Agents Revenue Forecast by Regions 2021-2026
12.2 North America Cardiovascular Agents Market Size Forecast (2021-2026)
12.2.1 North America: Cardiovascular Agents Sales Forecast (2021-2026)
12.2.2 North America: Cardiovascular Agents Revenue Forecast (2021-2026)
12.2.3 North America: Cardiovascular Agents Market Size Forecast by Country (2021-2026)
12.3 Europe Cardiovascular Agents Market Size Forecast (2021-2026)
12.3.1 Europe: Cardiovascular Agents Sales Forecast (2021-2026)
12.3.2 Europe: Cardiovascular Agents Revenue Forecast (2021-2026)
12.3.3 Europe: Cardiovascular Agents Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Cardiovascular Agents Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Cardiovascular Agents Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Cardiovascular Agents Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Cardiovascular Agents Market Size Forecast by Region (2021-2026)
12.5 Latin America Cardiovascular Agents Market Size Forecast (2021-2026)
12.5.1 Latin America: Cardiovascular Agents Sales Forecast (2021-2026)
12.5.2 Latin America: Cardiovascular Agents Revenue Forecast (2021-2026)
12.5.3 Latin America: Cardiovascular Agents Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Cardiovascular Agents Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Cardiovascular Agents Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Cardiovascular Agents Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Cardiovascular Agents Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Cardiovascular Agents Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Cardiovascular Agents Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Cardiovascular Agents Market Segments
Table 2. Ranking of Global Top Cardiovascular Agents Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Cardiovascular Agents Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Antianginal Agents
Table 5. Major Manufacturers of Antiarrhythmic Agents
Table 6. Major Manufacturers of Inotropic Agents
Table 7. Major Manufacturers of Miscellaneous Cardiovascular Agents
Table 8. Major Manufacturers of Peripheral Vasodilators
Table 9. Major Manufacturers of Renin Inhibitors
Table 10. Major Manufacturers of Sclerosing Agents
Table 11. Major Manufacturers of Vasodilators
Table 12. Global Cardiovascular Agents Market Size Growth Rate by Application 2020-2026 (K Units)
Table 13. Global Cardiovascular Agents Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 14. Global Cardiovascular Agents Sales by Regions 2015-2020 (K Units)
Table 15. Global Cardiovascular Agents Sales Market Share by Regions (2015-2020)
Table 16. Global Cardiovascular Agents Revenue by Regions 2015-2020 (US$ Million)
Table 17. Global Cardiovascular Agents Sales by Manufacturers (2015-2020) (K Units)
Table 18. Global Cardiovascular Agents Sales Share by Manufacturers (2015-2020)
Table 19. Global Cardiovascular Agents Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 20. Global Cardiovascular Agents by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cardiovascular Agents as of 2019)
Table 21. Cardiovascular Agents Revenue by Manufacturers (2015-2020) (US$ Million)
Table 22. Cardiovascular Agents Revenue Share by Manufacturers (2015-2020)
Table 23. Key Manufacturers Cardiovascular Agents Price (2015-2020) (USD/Unit)
Table 24. Cardiovascular Agents Manufacturers Manufacturing Base Distribution and Headquarters
Table 25. Manufacturers Cardiovascular Agents Product Type
Table 26. Date of International Manufacturers Enter into Cardiovascular Agents Market
Table 27. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 28. Global Cardiovascular Agents Sales by Type (2015-2020) (K Units)
Table 29. Global Cardiovascular Agents Sales Share by Type (2015-2020)
Table 30. Global Cardiovascular Agents Revenue by Type (2015-2020) (US$ Million)
Table 31. Global Cardiovascular Agents Revenue Share by Type (2015-2020)
Table 32. Cardiovascular Agents Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 33. Global Cardiovascular Agents Sales by Application (2015-2020) (K Units)
Table 34. Global Cardiovascular Agents Sales Share by Application (2015-2020)
Table 35. North America Cardiovascular Agents Sales by Country (2015-2020) (K Units)
Table 36. North America Cardiovascular Agents Sales Market Share by Country (2015-2020)
Table 37. North America Cardiovascular Agents Revenue by Country (2015-2020) (US$ Million)
Table 38. North America Cardiovascular Agents Revenue Market Share by Country (2015-2020)
Table 39. North America Cardiovascular Agents Sales by Type (2015-2020) (K Units)
Table 40. North America Cardiovascular Agents Sales Market Share by Type (2015-2020)
Table 41. North America Cardiovascular Agents Sales by Application (2015-2020) (K Units)
Table 42. North America Cardiovascular Agents Sales Market Share by Application (2015-2020)
Table 43. Europe Cardiovascular Agents Sales by Country (2015-2020) (K Units)
Table 44. Europe Cardiovascular Agents Sales Market Share by Country (2015-2020)
Table 45. Europe Cardiovascular Agents Revenue by Country (2015-2020) (US$ Million)
Table 46. Europe Cardiovascular Agents Revenue Market Share by Country (2015-2020)
Table 47. Europe Cardiovascular Agents Sales by Type (2015-2020) (K Units)
Table 48. Europe Cardiovascular Agents Sales Market Share by Type (2015-2020)
Table 49. Europe Cardiovascular Agents Sales by Application (2015-2020) (K Units)
Table 50. Europe Cardiovascular Agents Sales Market Share by Application (2015-2020)
Table 51. Asia Pacific Cardiovascular Agents Sales by Region (2015-2020) (K Units)
Table 52. Asia Pacific Cardiovascular Agents Sales Market Share by Region (2015-2020)
Table 53. Asia Pacific Cardiovascular Agents Revenue by Region (2015-2020) (US$ Million)
Table 54. Asia Pacific Cardiovascular Agents Revenue Market Share by Region (2015-2020)
Table 55. Asia Pacific Cardiovascular Agents Sales by Type (2015-2020) (K Units)
Table 56. Asia Pacific Cardiovascular Agents Sales Market Share by Type (2015-2020)
Table 57. Asia Pacific Cardiovascular Agents Sales by Application (2015-2020) (K Units)
Table 58. Asia Pacific Cardiovascular Agents Sales Market Share by Application (2015-2020)
Table 59. Latin America Cardiovascular Agents Sales by Country (2015-2020) (K Units)
Table 60. Latin America Cardiovascular Agents Sales Market Share by Country (2015-2020)
Table 61. Latin Americaa Cardiovascular Agents Revenue by Country (2015-2020) (US$ Million)
Table 62. Latin America Cardiovascular Agents Revenue Market Share by Country (2015-2020)
Table 63. Latin America Cardiovascular Agents Sales by Type (2015-2020) (K Units)
Table 64. Latin America Cardiovascular Agents Sales Market Share by Type (2015-2020)
Table 65. Latin America Cardiovascular Agents Sales by Application (2015-2020) (K Units)
Table 66. Latin America Cardiovascular Agents Sales Market Share by Application (2015-2020)
Table 67. Middle East and Africa Cardiovascular Agents Sales by Country (2015-2020) (K Units)
Table 68. Middle East and Africa Cardiovascular Agents Sales Market Share by Country (2015-2020)
Table 69. Middle East and Africa Cardiovascular Agents Revenue by Country (2015-2020) (US$ Million)
Table 70. Middle East and Africa Cardiovascular Agents Revenue Market Share by Country (2015-2020)
Table 71. Middle East and Africa Cardiovascular Agents Sales by Type (2015-2020) (K Units)
Table 72. Middle East and Africa Cardiovascular Agents Sales Market Share by Type (2015-2020)
Table 73. Middle East and Africa Cardiovascular Agents Sales by Application (2015-2020) (K Units)
Table 74. Middle East and Africa Cardiovascular Agents Sales Market Share by Application (2015-2020)
Table 75. AstraZeneca plc. Corporation Information
Table 76. AstraZeneca plc. Description and Major Businesses
Table 77. AstraZeneca plc. Cardiovascular Agents Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 78. AstraZeneca plc. Product
Table 79. AstraZeneca plc. Recent Development
Table 80. Pfizer Inc. Corporation Information
Table 81. Pfizer Inc. Description and Major Businesses
Table 82. Pfizer Inc. Cardiovascular Agents Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 83. Pfizer Inc. Product
Table 84. Pfizer Inc. Recent Development
Table 85. Novartis AG Corporation Information
Table 86. Novartis AG Description and Major Businesses
Table 87. Novartis AG Cardiovascular Agents Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 88. Novartis AG Product
Table 89. Novartis AG Recent Development
Table 90. Merck & Co., Inc. Corporation Information
Table 91. Merck & Co., Inc. Description and Major Businesses
Table 92. Merck & Co., Inc. Cardiovascular Agents Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 93. Merck & Co., Inc. Product
Table 94. Merck & Co., Inc. Recent Development
Table 95. Bristol-Myers Squibb Company Corporation Information
Table 96. Bristol-Myers Squibb Company Description and Major Businesses
Table 97. Bristol-Myers Squibb Company Cardiovascular Agents Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 98. Bristol-Myers Squibb Company Product
Table 99. Bristol-Myers Squibb Company Recent Development
Table 100. Bayer AG Corporation Information
Table 101. Bayer AG Description and Major Businesses
Table 102. Bayer AG Cardiovascular Agents Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 103. Bayer AG Product
Table 104. Bayer AG Recent Development
Table 105. Sanofi Corporation Information
Table 106. Sanofi Description and Major Businesses
Table 107. Sanofi Cardiovascular Agents Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 108. Sanofi Product
Table 109. Sanofi Recent Development
Table 110. Boehringer Ingelheim GmbH Corporation Information
Table 111. Boehringer Ingelheim GmbH Description and Major Businesses
Table 112. Boehringer Ingelheim GmbH Cardiovascular Agents Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 113. Boehringer Ingelheim GmbH Product
Table 114. Boehringer Ingelheim GmbH Recent Development
Table 115. F. Hoffmann-La Roche Ltd Corporation Information
Table 116. F. Hoffmann-La Roche Ltd Description and Major Businesses
Table 117. F. Hoffmann-La Roche Ltd Cardiovascular Agents Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 118. F. Hoffmann-La Roche Ltd Product
Table 119. F. Hoffmann-La Roche Ltd Recent Development
Table 120. Abbott Laboratories Corporation Information
Table 121. Abbott Laboratories Description and Major Businesses
Table 122. Abbott Laboratories Cardiovascular Agents Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 123. Abbott Laboratories Product
Table 124. Abbott Laboratories Recent Development
Table 125. Gilead Sciences, Inc. Corporation Information
Table 126. Gilead Sciences, Inc. Description and Major Businesses
Table 127. Gilead Sciences, Inc. Cardiovascular Agents Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 128. Gilead Sciences, Inc. Product
Table 129. Gilead Sciences, Inc. Recent Development
Table 130. Johnson & Johnson Corporation Information
Table 131. Johnson & Johnson Description and Major Businesses
Table 132. Johnson & Johnson Cardiovascular Agents Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 133. Johnson & Johnson Product
Table 134. Johnson & Johnson Recent Development
Table 135. Astellas Pharma, Inc. Corporation Information
Table 136. Astellas Pharma, Inc. Description and Major Businesses
Table 137. Astellas Pharma, Inc. Cardiovascular Agents Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 138. Astellas Pharma, Inc. Product
Table 139. Astellas Pharma, Inc. Recent Development
Table 140. Eli Lilly and Company Corporation Information
Table 141. Eli Lilly and Company Description and Major Businesses
Table 142. Eli Lilly and Company Cardiovascular Agents Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 143. Eli Lilly and Company Product
Table 144. Eli Lilly and Company Recent Development
Table 145. Otsuka Holdings Co., Ltd. Corporation Information
Table 146. Otsuka Holdings Co., Ltd. Description and Major Businesses
Table 147. Otsuka Holdings Co., Ltd. Cardiovascular Agents Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 148. Otsuka Holdings Co., Ltd. Product
Table 149. Otsuka Holdings Co., Ltd. Recent Development
Table 150. Takeda Pharmaceutical Company Limited. Corporation Information
Table 151. Takeda Pharmaceutical Company Limited. Description and Major Businesses
Table 152. Takeda Pharmaceutical Company Limited. Cardiovascular Agents Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 153. Takeda Pharmaceutical Company Limited. Product
Table 154. Takeda Pharmaceutical Company Limited. Recent Development
Table 155. Global Cardiovascular Agents Sales Forecast by Regions (2021-2026) (K Units)
Table 156. Global Cardiovascular Agents Sales Market Share Forecast by Regions (2021-2026)
Table 157. Global Cardiovascular Agents Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 158. Global Cardiovascular Agents Revenue Market Share Forecast by Regions (2021-2026)
Table 159. North America: Cardiovascular Agents Sales Forecast by Country (2021-2026) (K Units)
Table 160. North America: Cardiovascular Agents Revenue Forecast by Country (2021-2026) (US$ Million)
Table 161. Europe: Cardiovascular Agents Sales Forecast by Country (2021-2026) (K Units)
Table 162. Europe: Cardiovascular Agents Revenue Forecast by Country (2021-2026) (US$ Million)
Table 163. Asia Pacific: Cardiovascular Agents Sales Forecast by Region (2021-2026) (K Units)
Table 164. Asia Pacific: Cardiovascular Agents Revenue Forecast by Region (2021-2026) (US$ Million)
Table 165. Latin America: Cardiovascular Agents Sales Forecast by Country (2021-2026) (K Units)
Table 166. Latin America: Cardiovascular Agents Revenue Forecast by Country (2021-2026) (US$ Million)
Table 167. Middle East and Africa: Cardiovascular Agents Sales Forecast by Country (2021-2026) (K Units)
Table 168. Middle East and Africa: Cardiovascular Agents Revenue Forecast by Country (2021-2026) (US$ Million)
Table 169. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 170. Key Challenges
Table 171. Market Risks
Table 172. Main Points Interviewed from Key Cardiovascular Agents Players
Table 173. Cardiovascular Agents Customers List
Table 174. Cardiovascular Agents Distributors List
Table 175. Research Programs/Design for This Report
Table 176. Key Data Information from Secondary Sources
Table 177. Key Data Information from Primary Sources
List of Figures
Figure 1. Cardiovascular Agents Product Picture
Figure 2. Global Cardiovascular Agents Sales Market Share by Type in 2020 & 2026
Figure 3. Antianginal Agents Product Picture
Figure 4. Antiarrhythmic Agents Product Picture
Figure 5. Inotropic Agents Product Picture
Figure 6. Miscellaneous Cardiovascular Agents Product Picture
Figure 7. Peripheral Vasodilators Product Picture
Figure 8. Renin Inhibitors Product Picture
Figure 9. Sclerosing Agents Product Picture
Figure 10. Vasodilators Product Picture
Figure 11. Global Cardiovascular Agents Sales Market Share by Application in 2020 & 2026
Figure 12. Retail Pharmacies
Figure 13. Hospital Pharmacies
Figure 14. Online Pharmacies
Figure 15. Cardiovascular Agents Report Years Considered
Figure 16. Global Cardiovascular Agents Market Size 2015-2026 (US$ Million)
Figure 17. Global Cardiovascular Agents Sales 2015-2026 (K Units)
Figure 18. Global Cardiovascular Agents Market Size Market Share by Region: 2020 Versus 2026
Figure 19. Global Cardiovascular Agents Sales Market Share by Region (2015-2020)
Figure 20. Global Cardiovascular Agents Sales Market Share by Region in 2019
Figure 21. Global Cardiovascular Agents Revenue Market Share by Region (2015-2020)
Figure 22. Global Cardiovascular Agents Revenue Market Share by Region in 2019
Figure 23. Global Cardiovascular Agents Sales Share by Manufacturer in 2019
Figure 24. The Top 10 and 5 Players Market Share by Cardiovascular Agents Revenue in 2019
Figure 25. Cardiovascular Agents Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 26. Global Cardiovascular Agents Sales Market Share by Type (2015-2020)
Figure 27. Global Cardiovascular Agents Sales Market Share by Type in 2019
Figure 28. Global Cardiovascular Agents Revenue Market Share by Type (2015-2020)
Figure 29. Global Cardiovascular Agents Revenue Market Share by Type in 2019
Figure 30. Global Cardiovascular Agents Market Share by Price Range (2015-2020)
Figure 31. Global Cardiovascular Agents Sales Market Share by Application (2015-2020)
Figure 32. Global Cardiovascular Agents Sales Market Share by Application in 2019
Figure 33. Global Cardiovascular Agents Revenue Market Share by Application (2015-2020)
Figure 34. Global Cardiovascular Agents Revenue Market Share by Application in 2019
Figure 35. North America Cardiovascular Agents Sales Growth Rate 2015-2020 (K Units)
Figure 36. North America Cardiovascular Agents Revenue Growth Rate 2015-2020 (US$ Million)
Figure 37. North America Cardiovascular Agents Sales Market Share by Country in 2019
Figure 38. North America Cardiovascular Agents Revenue Market Share by Country in 2019
Figure 39. U.S. Cardiovascular Agents Sales Growth Rate (2015-2020) (K Units)
Figure 40. U.S. Cardiovascular Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 41. Canada Cardiovascular Agents Sales Growth Rate (2015-2020) (K Units)
Figure 42. Canada Cardiovascular Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 43. North America Cardiovascular Agents Market Share by Type in 2019
Figure 44. North America Cardiovascular Agents Market Share by Application in 2019
Figure 45. Europe Cardiovascular Agents Sales Growth Rate 2015-2020 (K Units)
Figure 46. Europe Cardiovascular Agents Revenue Growth Rate 2015-2020 (US$ Million)
Figure 47. Europe Cardiovascular Agents Sales Market Share by Country in 2019
Figure 48. Europe Cardiovascular Agents Revenue Market Share by Country in 2019
Figure 49. Germany Cardiovascular Agents Sales Growth Rate (2015-2020) (K Units)
Figure 50. Germany Cardiovascular Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. France Cardiovascular Agents Sales Growth Rate (2015-2020) (K Units)
Figure 52. France Cardiovascular Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. U.K. Cardiovascular Agents Sales Growth Rate (2015-2020) (K Units)
Figure 54. U.K. Cardiovascular Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Italy Cardiovascular Agents Sales Growth Rate (2015-2020) (K Units)
Figure 56. Italy Cardiovascular Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. Russia Cardiovascular Agents Sales Growth Rate (2015-2020) (K Units)
Figure 58. Russia Cardiovascular Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 59. Europe Cardiovascular Agents Market Share by Type in 2019
Figure 60. Europe Cardiovascular Agents Market Share by Application in 2019
Figure 61. Asia Pacific Cardiovascular Agents Sales Growth Rate 2015-2020 (K Units)
Figure 62. Asia Pacific Cardiovascular Agents Revenue Growth Rate 2015-2020 (US$ Million)
Figure 63. Asia Pacific Cardiovascular Agents Sales Market Share by Region in 2019
Figure 64. Asia Pacific Cardiovascular Agents Revenue Market Share by Region in 2019
Figure 65. China Cardiovascular Agents Sales Growth Rate (2015-2020) (K Units)
Figure 66. China Cardiovascular Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. Japan Cardiovascular Agents Sales Growth Rate (2015-2020) (K Units)
Figure 68. Japan Cardiovascular Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. South Korea Cardiovascular Agents Sales Growth Rate (2015-2020) (K Units)
Figure 70. South Korea Cardiovascular Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. India Cardiovascular Agents Sales Growth Rate (2015-2020) (K Units)
Figure 72. India Cardiovascular Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Australia Cardiovascular Agents Sales Growth Rate (2015-2020) (K Units)
Figure 74. Australia Cardiovascular Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Taiwan Cardiovascular Agents Sales Growth Rate (2015-2020) (K Units)
Figure 76. Taiwan Cardiovascular Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Indonesia Cardiovascular Agents Sales Growth Rate (2015-2020) (K Units)
Figure 78. Indonesia Cardiovascular Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Thailand Cardiovascular Agents Sales Growth Rate (2015-2020) (K Units)
Figure 80. Thailand Cardiovascular Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Malaysia Cardiovascular Agents Sales Growth Rate (2015-2020) (K Units)
Figure 82. Malaysia Cardiovascular Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Philippines Cardiovascular Agents Sales Growth Rate (2015-2020) (K Units)
Figure 84. Philippines Cardiovascular Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 85. Vietnam Cardiovascular Agents Sales Growth Rate (2015-2020) (K Units)
Figure 86. Vietnam Cardiovascular Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 87. Asia Pacific Cardiovascular Agents Market Share by Type in 2019
Figure 88. Asia Pacific Cardiovascular Agents Market Share by Application in 2019
Figure 89. Latin America Cardiovascular Agents Sales Growth Rate 2015-2020 (K Units)
Figure 90. Latin America Cardiovascular Agents Revenue Growth Rate 2015-2020 (US$ Million)
Figure 91. Latin America Cardiovascular Agents Sales Market Share by Country in 2019
Figure 92. Latin America Cardiovascular Agents Revenue Market Share by Country in 2019
Figure 93. Mexico Cardiovascular Agents Sales Growth Rate (2015-2020) (K Units)
Figure 94. Mexico Cardiovascular Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Brazil Cardiovascular Agents Sales Growth Rate (2015-2020) (K Units)
Figure 96. Brazil Cardiovascular Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 97. Argentina Cardiovascular Agents Sales Growth Rate (2015-2020) (K Units)
Figure 98. Argentina Cardiovascular Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 99. Latin America Cardiovascular Agents Market Share by Type in 2019
Figure 100. Latin America Cardiovascular Agents Market Share by Application in 2019
Figure 101. Middle East and Africa Cardiovascular Agents Sales Growth Rate 2015-2020 (K Units)
Figure 102. Middle East and Africa Cardiovascular Agents Revenue Growth Rate 2015-2020 (US$ Million)
Figure 103. Middle East and Africa Cardiovascular Agents Sales Market Share by Country in 2019
Figure 104. Middle East and Africa Cardiovascular Agents Revenue Market Share by Country in 2019
Figure 105. Turkey Cardiovascular Agents Sales Growth Rate (2015-2020) (K Units)
Figure 106. Turkey Cardiovascular Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. Saudi Arabia Cardiovascular Agents Sales Growth Rate (2015-2020) (K Units)
Figure 108. Saudi Arabia Cardiovascular Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 109. U.A.E Cardiovascular Agents Sales Growth Rate (2015-2020) (K Units)
Figure 110. U.A.E Cardiovascular Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 111. Middle East and Africa Cardiovascular Agents Market Share by Type in 2019
Figure 112. Middle East and Africa Cardiovascular Agents Market Share by Application in 2019
Figure 113. North America Cardiovascular Agents Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 114. North America Cardiovascular Agents Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Europe Cardiovascular Agents Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 116. Europe Cardiovascular Agents Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Asia Pacific Cardiovascular Agents Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 118. Asia Pacific Cardiovascular Agents Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Latin America Cardiovascular Agents Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 120. Latin America Cardiovascular Agents Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 121. Middle East and Africa Cardiovascular Agents Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 122. Middle East and Africa Cardiovascular Agents Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 123. Porter's Five Forces Analysis
Figure 124. Channels of Distribution
Figure 125. Distributors Profiles
Figure 126. Bottom-up and Top-down Approaches for This Report
Figure 127. Data Triangulation
Figure 128. Key Executives Interviewed
マイクロバブル/超音波造影剤の世界市場（～2026年） Microbubbles/ultrasound contrast agents are small spherical bubbles comprised of three phases, namely innermost gas phase, shell material enclosing the gas phase, and outermost gas or liquid phase. These microbubbles have unique ability to respond to ultrasound; thereby used for ultrasound imaging a…- 固結防止剤の世界市場（～2026年） Anti-caking agents are utilized to prevent the formation of lumps, mostly in finely powdered substances. Anti-caking agents are soluble in alcohol, water and other organic solvents. They either absorb excess moisture or create a water-repellent coating on the powdered particles. Asia Pacific is expe…
- 分子イメージング剤の世界市場（～2026年） Molecular imaging is a new biomedical research discipline which enables the quantification, visualization, and characterization of biologic processes taking place at the cellular and subcellular levels. Molecular imaging plays a very important role in diagnosis of early assessment, risk stratificati…
- MRI造影剤の世界市場（～2026年） MRI contrast agents are contrast agents used to improve the visibility of internal body structures in magnetic resonance imaging (MRI). The most commonly used compounds for contrast enhancement are gadolinium-based. Such MRI contrast agents shorten the relaxation times of nuclei within body tissues …
- サイジングおよび増粘剤の世界市場（～2026年） Sizing agents are substances that are commonly applied to fibers to reduce their porosity and make them suitable for printing. Thickening agents improve the viscosity of fluids without changing other properties. They are commonly used by the F&B industry to increase the viscosity of liquids. Based o…